Common second-line therapies for type 2 diabetes include dipeptidyl peptidase-4 (DPP4) inhibitors, SGLT2 inhibitors, and GLP1 receptor agonists [8, 9]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.